CTNM vs CVM

Contineum Therapeutics, Inc. vs Cel-Sci Corporation — Valuation Comparison 2026

CTNM

Biotechnology
Contineum Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
12
SAFE
Price
$13.31
Last close
Models
7/13
Active
VS

CVM

Biotechnology
Cel-Sci Corporation
Quality
3.3
out of 10
Value Trap
24
SAFE
Price
$1.48
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CTNM Fair ValueCTNM Upside CVM Fair ValueCVM Upside
Bayesian DCF Intrinsic $0.26 -98.2% $0.02 -98.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $4.05 -69.6% $0.12 -94.8%
Dynamic NAV Asset-Based $3.43 -74.0% $1.75 +18.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTNM vs CVM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTNM vs CVM — Which Stock Is More Undervalued?

CTNM scores higher with a 4.6/10 quality rating vs CVM's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Contineum Therapeutics, Inc. (CTNM) and Cel-Sci Corporation (CVM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTNM currently trades at $13.31 with a QOC of 4.6/10, while CVM trades at $1.48 with a QOC of 3.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).